Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selective anti-VEGF (Macugen) or Pan anti-VEGF (Avastin). - ND

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2009年12月11日最近更新: 2014年2月3日

试验速览

暂无简介。

•- age beetween 50 and 80
•- wet AMD with choroidal neovascularization
•- absence of: any possibile systemic causes of vasculopathy, any vascular disorders of the retina and choroid, previous intravitreal drug injections, previous eye surgery.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•. previous eye surgery
•. any changes at the cornea and lens level which interfere with a good visualization of fundus.
•. previous intravitreal drug injections
•. any possibile systemic causes of periferic vasculopathy
•. hypersensitivity to the drug in study
•. women in pregnancy and breast-feeding or women who have intention of having one pregnancy in the period of time of duration of the study
•. prior treatment for CNV secondary to AMD in the study eye including PDT or Argon laser

发起方

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)